Novo Nordisk A/S (NVO) Stock

NYSE
HealthcareDrug Manufacturers - General Website

NVO has an Alpha Score of 41 out of 100 (weak), computed on Nov 21, 2026 from 3 of 4 sub-scores. 15 members of Congress disclosed 36 trades in NVO since 2016: 18 purchases and 18 sales, most recently Kevin Hern (sale, Sep 10, 2026). 6 of the hedge funds AlphaScala tracks reported NVO in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Citadel's at $265.80M. Its trailing P/E ratio is 10.3 and its net margin 35.4% (key statistics as of Nov 12, 2026).

$37.82
-2.70%
Last price
Source: Finnhub
Alpha Score
41
Weak

What is NVO's Alpha Score?

How it works →

Alpha Score of 41 reflects weak overall profile with poor momentum, moderate value, strong quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.

Momentum
21
Poor
Value
51
Weak
Quality
70
Moderate

Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.

Computed Nov 21, 2026

A rules-based research rating, not a recommendation to buy or sell.

Which members of Congress traded Novo Nordisk A/S (NVO)?

Members
15
Disclosed trades
36
Purchases
18
Sales
18

Most recent: Kevin Hern (sale, Sep 10, 2026); records start Oct 11, 2016.

PoliticianTrade dateTypeAmount
Kevin Hern
R-OK · House
2026-09-10sale$1k – $15k
Kevin Hern
R-OK · House
2026-08-31partial sale$1k – $15k
Scott Franklin
R-FL · House
2026-08-26purchase$1k – $15k
Alan Armstrong
R-OK · Senate
2026-03-30purchase$15k – $50k
Lisa McClain
R-MI · House
2025-10-31sale$1k – $15k
Lisa McClain
R-MI · House
2025-10-30purchase$1k – $15k
Lisa McClain
R-MI · House
2025-10-30sale$1k – $15k
Marjorie Taylor Greene
R-GA · House
2025-10-15purchase$1k – $15k

From STOCK Act periodic transaction reports. House filings as of Nov 19, 2026.

Every member of Congress who traded NVO, with filing lags →

Which hedge funds own NVO?

From 13F filings
FundShares HeldPosition ValueChange vs prior Q
Citadel
Ken Griffin
7.01M$265.80M+413%
Renaissance Technologies
Jim Simons (founder)
4.68M$177.28M+54%
Marshall Wace2.16M$81.95M+27%
Millennium Management
Israel Englander
2.15M$81.51M+6%
Point72
Steve Cohen
320K$12.12M+995%
D.E. Shaw
David Shaw
54K$2.03M-92%

13F holdings as of Sep 30, 2026

Explore all tracked funds →

What are NVO's key statistics?

P/E Ratio
10.34
EPS (TTM)
26.18
Dividend Yield
1.00%
Beta
1.85
Net Margin
35.35%
ROE
59.09%
Debt / Equity
0.67
52W High
$409.95
52W Low
$224.25

Key statistics as of Nov 12, 2026

How does NVO's valuation compare with the Healthcare sector?

MetricNVOHealthcare medianCompanies in median
P/E ratio10.329.1147
Net margin35.35%3.59%223
Return on equity59.09%3.41%255
Dividend yield (payers)1.00%1.37%61

Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 22, 2026). P/E excludes loss-making companies.

What moved NVO recently?

AI-written from the data on this page

Novo Nordisk trades flat near 52-week low as growth slows

Novo Nordisk shares slipped 0.07% to $41.60 on Nov. 16, holding near the bottom of a 52-week range that stretches from $224.25 to $409.95. The stock has shed roughly 82% from its high as revenue growth decelerated to 5.6% year over year and EPS growth slowed to 4.9%. Net margin remains strong at 35.4%. The Alpha Score of 42.6 reflects weak momentum at 24.4, offset by quality at 70.3 and value at 51.9. The P/E of 10.34 is well below the sector median. Investors will watch for any update on pipeline catalysts or demand trends for GLP-1 products in the coming weeks.

NVO price chart

Powered by TradingView

What does Novo Nordisk A/S do?

Novo Nordisk is a leading global pharmaceutical company headquartered in Denmark that specializes in developing and manufacturing medicines to treat serious chronic diseases. The company focuses on four primary therapeutic areas: diabetes, obesity, cardiovascular disease, and rare diseases including hemophilia and growth disorders. Its product portfolio includes diabetes treatments like Tresiba and Rybelsus, obesity medications such as Wegovy, cardiovascular and rare disease therapies, and hormone replacement treatments. Novo Nordisk operates manufacturing facilities across multiple continents and maintains research and development centers worldwide, serving millions of patients globally. The company is backed by the Novo Nordisk Foundation, one of the world's largest philanthropies, which influences its approach to healthcare innovation and patient access. Founded on principles emphasizing scientific excellence and compassion, Novo Nordisk combines breakthrough pharmaceutical research with a commitment to expanding medicine accessibility and working toward disease prevention and cure.

CEO
Mr. Maziar Mike Doustdar B.A.
Employees
68,794
Market Cap
$1.20T
Ask about NVOAI research agent